PHG | Strong Positive Volume | LONGKoninklijke Philips N.V. operates as a health technology company in North America and internationally. It operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. The company provides diagnostic imaging solutions, includes magnetic resonance imaging, computed tomography (CT) systems, X-ray systems, and detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; integrated interventional systems; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. It also offers acute patient management solutions; emergency care solutions; sleep and respiratory care solutions; and electronic medical record and care management solutions. In addition, the company provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding and digital parental solutions; and male grooming and beauty products and solutions. It has a strategic collaboration with Ibex Medical Analytics Ltd. to jointly promote the digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide, as well as a strategic partnership agreement with NICO.LAB. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.
Healthcare
CLNN | Lets Get It | Extremely OversoldClene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Specialized education that secures jobs equals +100% from lowsAdtalem Global Education is a leading healthcare educator that partners with organizations to address workforce needs and empower career development across the medical and healthcare industries.
I've been watching this stock for a while and finally is signaling an actionable pivot buy.
Price is close to its 50-day MA which can act as a good support level. I'd place mi stop just below it.
Yesterday's volume was above average so I'll wait until near the close to assess today's volume.
This stock is up +100% from its February low, that's right it bottomed in February.
If this is not leadership, don't know what it is.
10/23/22 HUMHumana Inc. ( NYSE:HUM )
Sector: Health Services (Managed Health Care)
Market Capitalization: 64.611B
Current Price: $510.54
Breakout price trigger: $515.20
Buy Zone (Top/Bottom Range): $496.45-$473.95
Price Target: $562.30-$568.90
Estimated Duration to Target: 147-156d
Contract of Interest: $HUM 1/20/23 520c
Trade price as of publish date: $26.20/contract
RAD Q4 buying means 2023 Q2 selling for multiplesThis is chart analysis only, the business fundamentals feel distressed to me however this is a meme stock and it can easily run up
Buying today under $4.20 seems decent but i think there will be lower lows soon
RVP | RSI Curling Upward | LONGRetractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally. It offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes. The company distributes its products through general line and specialty distributors, as well as through international distributors; and a direct marketing network. Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas.
Are you looking for stocks to buy? I am $PCTY $CCRNThe thing is, I'm buying very small positions.
I use the averages like the SP:SPX and NASDAQ:IXIC more like a sentiment measure. The averages are that, averages. They don't account for the whole market.
There will always be stocks rising or falling regardless of what the indexes are doing. But, if the averages are in downtrends I won't buy aggressively.
I like these two stocks, NASDAQ:PCTY and NASDAQ:CCRN . They are both leaders in the outsorcing industry. Coincidence?
Cross Country HealthCare provides market-leading workforce solutions and healthcare staffing services. And Paylocity provides software for payroll solution designed for the employee experience.
I'll buy a close above Friday's high with a stop loss just below the Friday's low. Also I'll be watching volume very closely as in both momentum is still bullish.
10/5/22 RVNCRevance Therapeutics, Inc.( NASDAQ:RVNC )
Sector: Health Technology (Pharmaceuticals: Major)
Market Capitalization: $2.124B
Current Price: $29.17
Breakout price: $30.00
Buy Zone (Top/Bottom Range): $27.45-$24.15
Price Target: $41.10-$42.00
Estimated Duration to Target: 132-142d
Contract of Interest: $RVNC 1/20/23 30c
Trade price as of publish date: $3.70/contract
$HUM, $XLV, Healthcare sector worth watching nowIf you have been invested in healthcare stocks or ETF's you may want to take profits between now and the end of October. I am keeping an eye on this chart for some good trades. It is a low volume stock with very low options volume, so be very selective with your entry time/place and your option price. Daily trading ranges can be large or small, so give extra consideration to time frame and holding time in your trade plan.
Please note on the chart:
* Linear regression channel shown from 2019
* Yellow dashed lines showing 370-470 trading range
* Light yellow rectangle shows two-year range which was recently broken higher
* White line (channel center) regularly acts as support or resistance, price is wavering along this line
* RSI only had one instance of going over 67 (white oval) or under 33 since 2019, and that resulted in sharp reversal, for now it is moving lower
* Stochastic %D has completed three peaks since dipping below 30 and is now turning down
Price was weak on Monday and closed lower, but still in its recent range (sideway. I am looking at a few possibilities for trades:
* If the market rallies this week HUM may stay under the white line and selloff down to 457, 435
* If the anticipated October leg down occurs, then price may move up to analysts' 550 price target (also top of channel)
* Price has been sideways for two weeks, so it should move higher/lower soon
8 Reasons Why Medtronic is a Great Investment OptionMedtronic is a medical device company that focuses on research, development, manufacturing, and distribution of various medical devices. The company has grown rapidly in the last few years thanks to its strong performance and focus on innovation. In this article, we will discuss why Medtronic remains a strong investment option with a promising future ahead.
Reasons to invest in Medtronic
The strong financial position of Medtronic is one of the main reasons to invest in it. The company’s debt-to-equity ratio is below 1.0, which means that its debt is well below its equity base. This is an important ratio to watch as an investor, especially if the company is heavy on debt – as that indicates that the company may run into trouble in the future especially in times like these where interest rates are going up. The company’s return on equity (ROE) is consistently above its cost of equity, which means that it is earning much more than its shareholders could expect in a risk-free investment. Similarly, Medtronic’s debt-to-asset ratio is below 40%, which shows that its debt is lower than its assets. This is important to look at when evaluating a company’s financial position, as it indicates the company is mostly likely to be able to pay back its debt even in a worst-case scenario.
Strong Financial Position
Another factor to consider when evaluating a company’s financial position is its liquidity. Liquidity is the ability of a company to quickly turn its assets into cash if needed. When it comes to Medtronic, the company has enough liquidity thanks to its cash on hand, cash from operations, and other short-term investments that can easily be turned into cash. Similarly, Medtronic’s current ratio (the number of current assets compared to current liabilities) is above 1.0, which indicates that the company has enough current assets to meet its current liabilities. This ratio is important to look at because it indicates whether or not a company can meet its short-term obligations while also pursuing long-term goals.
Strong Track Record of Growth Through Acquisitions
Medtronic has a strong track record of growth through acquisitions, having acquired dozens of companies in its history. This is important to watch out for when investing in a company – especially if it has a history of poor acquisitions. This can lead to lost capital for investors as well as a company that is unfocused. However, the acquisitions Medtronic has made have all been successful and focused around the company’s core business. This has allowed Medtronic to offer a wide range of products around the world while also keeping its R&D focused on the most important innovations.
Integration of CareLink with Guardian 2 platform
Another example of a successful acquisition is when Medtronic purchased CareLink in 2015 for $250 million. CareLink is a company focused on creating remote patient monitoring solutions that are designed to help patients manage chronic diseases at home. Following the acquisition, CareLink was integrated into Medtronic’s Guardian 2 remote care platform, which connects patients and doctors while also allowing patients to monitor their own health. This represents a huge opportunity for Medtronic as it expands its remote monitoring capabilities. This is especially relevant as more and more people are living with chronic conditions that require consistent monitoring. This is expected to lead to a huge opportunity for remote monitoring solutions in the future.
Solid Return on Investment for Medtronic Investors
When looking at the company’s return on investment (ROI), it is important to note that this is a long-term number. This means that you want to see a high ROI, but this number is not as important as a company’s short-term numbers. However, when it comes to investment, the long-term numbers are actually more important than the short-term numbers. The short-term numbers are important because they indicate how strong of a short-term investment a company is. The long-term numbers are important because they show the potential for long-term growth.
Solid Base of Popular Brands/Products for Medtronic
Another important factor to look at when evaluating Medtronic is its core products and brands. These are the products and brands that define Medtronic as a company, and they are what has helped the company grow over the last few decades. These products/brands can give us insight into Medtronic’s future plans, because the company has to consistently update and improve these products to meet consumer demand.
Medtronic is venturing into the artificial intelligence space
One of the biggest trends in the medical device industry is the adoption of artificial intelligence (AI). AI can be used to help medical devices better understand their environment and collect data/information on patients while also allowing them to communicate with other devices. This can be extremely helpful in the medical device industry, especially when it comes to remote monitoring solutions – which is an area in which Medtronic is already growing. One of Medtronic’s key acquisitions in recent years was HealthMine, which is a company focused on the AI space within medical devices. This acquisition could allow Medtronic to significantly expand its AI capabilities and help the company keep up with the latest trends in its industry.
Financials
EPS
Dividend Yield %
Valuation Metrics
Summing up
There are many reasons why Medtronic is a great investment option. The company has a strong financial position, a strong track record of growth through acquisitions, an integration of its CareLink acquisition with its Guardian 2 platform, a solid base of popular brands/products for Medtronic, and Medtronic is venturing into the artificial intelligence space. These are all reasons to invest in Medtronic because they show a strong future ahead.
AHPI | Under-valued PlayAllied Healthcare Products, Inc. manufactures and markets respiratory products for use in the health care industry in a range of hospitals and alternate site settings worldwide. The company offers respiratory care/anesthesia products, including air compressors, calibration equipment, humidifiers, croup tents, and equipment dryers, as well as respiratory disposable products, such as oxygen tubing products, facemasks, cannulas, and ventilator circuits; and home respiratory care products comprising aluminum oxygen cylinders, oxygen regulators, pneumatic nebulizers, portable suction equipment, and a line of respiratory disposable products. It also provides medical gas equipment, which include construction products consisting of in-wall medical system components, central station pumps and compressors, and headwalls; regulation devices and suction equipment comprising flowmeters, vacuum regulators, and pressure regulators, as well as related adapters, fittings, and hoses that measure, regulate, monitor, and transfer medical gases from walled piping or equipment to patients; and disposable oxygen cylinders to provide oxygen for short periods. In addition, the company offers emergency medical products that include respiratory/resuscitation products, such as demand resuscitation valves, portable resuscitation systems, bag masks and related products, emergency transport ventilators, precision oxygen regulators, minilators, multilators, and humidifiers; and trauma and patient handling products that include spine immobilization products, pneumatic anti-shock garments, and trauma burn kits. It serves hospitals, hospital equipment dealers, hospital construction contractors, home health care dealers, emergency medical products dealers, and others. The company was incorporated in 1979 and is headquartered in St. Louis, Missouri.
HCAT Technical trade THIS IS NOT ADVICEThis ticker looks to be expanding its name with recent acquisitions, but the real reason for the trade is technical in nature, with clear momentum to the upside, horizontal resistance levels being turned to support, bullish divergence on the longer time frame, technicals are setup to look for a return to previous levels off the backs of a strong Bulldiv rally from oversold levels, setting a stop below the recent swing low allows for a technical trade plan that removes emotion. The slightly impressive R/R lines up with the bottom of the recent march low making it conservative, too. if the position is large enough, it could be managed through selling calls and use the premiums to hedge against a drop, just close out any short calls before dumping shares and make sure any short calls are initially sold with a strike above entry. AS ALWAYS!! make sure that any calls sold are done so with a full understanding of any possible dividend liabilities or obligations.
NOT ADVICE, SIMPLY FOR FUN AND THEORY
Veeva SystemsThis is a daily chart of Veeva Systems (VEEV), a healthcare technology company that provides cloud solutions for the global life sciences industry.
When the company reported its earnings on August 31st the stock price subsequently gapped down, as shown in the chart above. From a probability standpoint, this gap is likely to be filled for the reasons below.
1. The gap is a monthly candle gap and these usually close.
Unfilled gaps on the monthly charts are generally quite rare, especially for assets that have never left a monthly gap before. As shown in the chart below, VEEV has never left a gap on its monthly chart before.
2. The gap is below the lower regression channel line. A regression channel is used to measure how far above or below an asset is trading from its mean. Since price generally tends to mean revert, it's highly unlikely that a gap below the lower channel line, (which in this case represents two standard deviations below the mean), will never be filled. It's more likely that the gap will not only be filled, but will be filled quite rapidly. The assumption I make in using this regression channel is that it is statistically valid and data are normally distributed. If true, then there's only a small probability that VEEV's monthly candle will close the month so far below the lower line of the regression channel. Therefore, it's likely that price will be drawn back up to the mean, and thus the gap will be filled.
Here's a close up view:
3. Price gapped below an important Fibonacci level that has been holding, and likely will continue to hold, as support. See the chart below.
Here are some close up views:
At a minimum, price will very likely push back into the 180s.
The quarterly chart shows long lower wicks at this Fibonacci level, indicating that it is holding as support. With further momentum to the downside waning as shown by the Stochastic RSI, there's little reason to believe this Fibonacci level will fail this time.
The lower wicks on the quarterly candles are also bouncing off of the exponential moving average (EMA) ribbon, which usually acts as support when price descends to it from above.
Strategy
With this said, I noticed that someone is already sweeping the call options. They swept hundreds of out-of-the-money (OTM) call options expiring on 9/16 with a $180 strike. Clearly, this buyer believes that VEEV's price is poised to quickly return at least to the Fibonacci support level of $180.97.
If you don't know what an options sweep is, it simply refers to an instance in which options are purchased right at the ask price. In most cases, buyers place a limit buy at the mid point of the bid-ask spread or at a lower target price. Market participants usually only buy at the ask price if they're in a rush to buy and/or if they have a high confidence about a certain market move and want to guarantee their entry while also not tipping the market off about their anticipated market move. Sweeps can also refer to when a large buyer wants to obfuscate their entry by splitting their large order into a lot of smaller parts to sweep the entire order book without tipping off the market as they would have if they placed a single large limit order. Understanding sweeps can help you understand what smart money is doing. It's very rare that retail traders sweep the order book because it's very expensive, and for a smaller portfolio (less than a million) it can be extremely risky. Therefore, smart money is usually the market participant who sweeps the order book.
Personally, I find this call sweep to be risky (assuming that it's not part of some kind of a hedge) since although we have a high confidence that the gap may close, we don't know within what time frame it will do so. Rather than sweeping a call option with a strike price of $180 that expires on 9/16 a safer though less lucrative trade would be to sell a cash-secured put with a strike price of $180 and which expires on 9/16. Doing this gives you much higher odds of winning but is profit limited.
If the price goes to $180 or higher at expiration, you win the full premium since the put you sold will not be exercised.
If the price is below $180 but above the breakeven price at expiration, or if the price is below even your breakeven price, then you may be forced to buy shares of VEEV at $180, but you can simply hold those shares until the gap closes (or longer if you think price is going higher). Therefore in this case you still do not lose money, and still make the premium as profit.
The only plausible scenario whereby you would lose money would be if VEEV's price continued to plummet and never recovers. Although this would be incredibly unlikely, it is still possible. You can nonetheless still hedge against even this risk by using a put spread to limit loss potential to a ratio that meets your risk management strategy. Therefore you can safely take a very high probability trade while managing risks well. Successful trading is mostly determined by how well you manage risks.
Finally, since options are leveraged, one should always try to time their entry as perfectly as possible by using shorter timeframe (hourly or 4-hour) charts, especially if the option's expiration is close. For example, you can see that the 4 hour chart for VEEV is showing momentum building back to the upside. This is what you want to see if you're going to sell a put option strategy that expires on 9/16.
These are just my thoughts and they are definitely not meant to be trading advice. As always, anything can happen. September can often be a volatile month and is prone to declines. Options trading is risky and can result in complete loss. Trade at your own risk.
If you would like me to post more strategies like this on here leave a boost or a comment below so I can gauge interest. Thank you.
If you're new to trading and don't understand the options trading language that I used above, I would recommend Project Finance to learn about options. I learned a ton about options trading from this channel and the content is always high-quality: www.youtube.com
If you want to learn more about the basics of trading, you can see my post linked below for 10 rules for successful trading.
Roche Holding AG bullish scenario:The technical figure Triangle can be found in the daily chart in the German company F. Hoffmann-La Roche AG (ROG.vx). Roche is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. Roche is the fifth largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. The Triangle broke through the resistance line on 07/09/2022, if the price holds above this level, you can have a possible bullish price movement with a forecast for the next 10 days towards 333.65 CHF. Your stop-loss order, according to experts, should be placed at 311.75 CHF if you decide to enter this position.
Roche announced the launch of the Digital LightCycler System, Roche’s first digital polymerase chain reaction (PCR) system. This next-generation system detects disease and is designed to accurately quantify trace amounts of specific DNA and RNA targets not typically detectable by conventional PCR methods.
The Digital LightCycler System will allow clinical researchers to divide DNA and RNA from an already extracted clinical sample into as many as 100,000 microscopic individual reactions. The system can then perform PCR and produce highly sophisticated data analysis on the results.
Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
$AMLX, following the Bio TechsThe health care industry is being leading the charge, NASDAQ:AMLX is the proof of that. This recent IPO just broke out of a good looking cup & handle pattern. Also, IBD is giving a 99 relative strength rating.
So, I enter today with a small position. A "pilot position", as Mark Minervini would say. The market is still under pressure so I'm testing it.
As this stock is a highly volatile I'll play for a 3:1 risk/reward.
Healthcare leader $PRGO making a shark pattern Perrigo is in the Medical-Generic Drugs Group, they develop, manufactures, markets, and distributes private label self-care products, including cough, cold, and allergy products, analgesics, gastrointestinal products, smoking cessation products, infant formula and food products.
IBD gives it a #1 rank in its industry.
PRGO made its major low in May while XLV made it in late June. That's very good relative strength. Now, after the price broke above its 200-day MA, its been forming a base giving a good opportunity to buy.
The price is making shark pattern with a pivot buy at $43.01. I'll leave a STOP BUY at that level.
$MASS, growth stock close to breakout908 Devices Inc is in the Medical-Research Eqp/Svc Group. It develops analytical devices for chemical and biomoecular solutions.
The price made a shortfall within the channel that has been forming since January. This shortfall may signal a breakout in the right direction.
I would buy it with a target sell at its next resistance level which is at $29, that's a +20% profit. Play this trade with your own risk/reward strategy. I'm sure I will.
Also just recently, the company tweeted: "Proud to share our #MX908 device was chosen by the U.S. Army to provide chemical identification in their #AugmentedReality training program, ensuring optimal safety when encountering unidentified substances".
3M Company (MMM) bullish scenario:The technical figure Falling Wedge can be found in the daily chart in the US company 3M Company (MMM). The 3M Company is an American multinational conglomerate corporation operating in the fields of industry, worker safety, U.S. health care, and consumer goods. The company produces over 60,000 products under several brands, including adhesives, abrasives, laminates, passive fire protection, personal protective equipment, window films, paint protection films, dental and orthodontic products, electrical and electronic connecting and insulating materials, medical products, car-care products,electronic circuits, healthcare software and optical films. The Falling Wedge has broken through the resistance line on 27/07/2022, if the price holds above this level, you can have a possible bullish price movement with a forecast for the next 27 days towards 155.52 USD. Your stop-loss order, according to experts, should be placed at 125.60 USD if you decide to enter this position.
3M Co. said it would spin off its healthcare business as a public company and sought bankruptcy protection for a subsidiary that once produced military earplugs that thousands of veterans now blame for damaging their hearing.
The moves Tuesday attempt to address the industrial conglomerate’s lingering overhangs with sluggish growth of its businesses and an increasing exposure to costs for lawsuits.
The company said it has committed $1 billion to fund a trust to pay claims about its earplugs and $240 million to fund expected expenses related to the cases. 3M said it would provide more funding if required. The company filed for bankruptcy for Aearo Technologies, a subsidiary that once made the earplugs, as a way to fence off the litigation from the rest of 3M.
Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.